期刊
PHARMACOGENOMICS JOURNAL
卷 9, 期 3, 页码 175-184出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2009.9
关键词
CYP2D6; metoprolol; heart failure; beta-adrenoceptor antagonists; pharmacogenetics
资金
- New Zealand Pharmacy Education and Research Foundation
- Jim and Mary Carney Charitable Trust
- Danish Medical Research Council
- Department of Science, Innovation and Technology, Denmark [271-06-0698]
- Sir Charles Hercus Research Fellowship (Health Research Council of New Zealand)
The aims of this study were to examine the relationships between CYP2D6 genotype and metoprolol dose, S- and R- metoprolol concentrations and clinical effects in patients with systolic heart failure. Data were obtained for 52 subjects, of which 27 had 2 functional alleles (24/27, CYP2D6*1/*1), 22 had 1 functional allele (18/22, CYP2D6*1/*4) and 3 had no functional alleles (CYP2D6*4/*4). Median dose-adjusted concentrations of S- metoprolol (active) were 6.3- and 3.2-fold higher in subjects with zero or one functional allele (P = 0.016 and P = 0.006), respectively, compared with subjects with two functional alleles. For the R- enantiomer (inactive), these concentrations were 10.7- and 3.7-fold higher (P = 0.013 and P = 0.003), respectively. Despite clear gene-concentration differences, no relationships between CYP2D6 genotype and dose or clinical effects could be shown. Although the number with no functional alleles was too small (n = 3) to show effects, in patients with 1 functional allele other sources of variance are likely to be obscuring differences in clinical effects. The Pharmacogenomics Journal (2009) 9, 175-184; doi:10.1038/tpj.2009.9; published online 14 April 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据